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For almost 20 years, apoptosis and secondary necrosis have been considered the major
source of autoantigens and endogenous adjuvants in the pathogenic model of systemic
autoimmune diseases. This focus is justiﬁed in part because initial evidence in systemic
lupus erythematosus (SLE) guided investigators toward the study of apoptosis, but also
because other forms of cell death were unknown. To date, it is known that many other
forms of cell death occur, and that they vary in their capacity to stimulate as well as inhibit
the immune system. Among these, NETosis (an antimicrobial form of death in neutrophils
in which nuclear material is extruded from the cell forming extracellular traps), is gaining
major interest as a process that may trigger some of the immune features found in SLE,
granulomatosis with polyangiitis (formerly Wegener’s granulomatosis) and Felty’s
syndrome. Although there have been volumes of very compelling studies published on
the role of cell death in autoimmunity, no unifying theory has been adopted nor have
any successful therapeutics been developed based on this important pathway. The recent
inclusion of NETosis into the pathogenic model of autoimmune diseases certainly adds
novel insights into this paradigm, but also reveals a previously unappreciated level of
complexity and raises many new questions. This review discusses the role of cell death in
systemic autoimmune diseases with a focus on apoptosis and NETosis, highlights the
current short comings in our understanding of the vast complexity of cell death, and
considers the potential shift in the cell death paradigm in autoimmunity. Understanding
this complexity is critical in order to develop tools to clearly deﬁne the death pathways that
are active in systemic autoimmune diseases, identify drivers of disease propagation, and
develop novel therapeutics.
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INTRODUCTION
A hallmark feature of systemic autoimmune diseases is the cir-
culation of autoantibodies that recognize intracellular antigens
thought to be expressed by all cells, yet are strikingly associated
with speciﬁc disease phenotypes and outcomes. These diseases
include systemic lupus erythematosus (SLE), rheumatoid arthritis
(RA), Sjögren’s syndrome (SS), autoimmune myopathies, sys-
temic vasculitis, and scleroderma. The ubiquitous expression of
many autoantigens and their diverse intracellular function and
distribution has long posed a problem in understanding the mech-
anisms by which these proteins become targets of the autoimmune
response. It stands to reason that several requirements must be
met in order for immune tolerance to be broken to a self-protein:
(i) accessibility of the antigen to the immune system; (ii) presence
of proinﬂammatory factors or motifs; and (iii) non-homeostatic
state of the protein/altered self (i.e., increased levels of expres-
sion or modiﬁed protein sequence/structure). Cell death has long
been implicated in this process, and for historical reasons, apop-
tosis has been the most widely studied. However, the recent
ﬁnding that NETosis can reproduce critical immune features ini-
tially ascribed to apoptosis in systemic autoimmune diseases has
exposed a previously unrecognized level of complexity in the role
of cell death in autoimmunity. Indeed, virtually every form of
physiologic cell death that has been described has the potential
to meet these requirements, especially in the setting of clearance
defects impairing the efﬁcient and rapid removal of dead cells.
Before we lay a framework implicating cell death pathways in
the initiation and propagation of systemic autoimmune diseases,
it is critical to point out that cell death and damage is a nor-
mal and necessary process in a multi-cellular organism. From an
evolutionary perspective, no physiologic form of death should
have deleterious effects to the host. Any form of cell death, be it
organized and planned (i.e., apoptosis) or spectacular and fright-
ening (i.e., NETosis), is physiologic. Redundant mechanisms have
evolved to ensure rapid and efﬁcient clearance of dead cell corpses
anddebris, anddevelopment of immune tolerance to self-proteins.
Therefore, no form of cell death should have an autoimmune
advantage over any other mode of death, unless speciﬁc host
abnormalities related to unique forms of death exist. The develop-
ment of autoimmune diseases is known to be highly complex and
likely involves the contribution of several genetic and environmen-
tal components. Due to this unlikely conﬂuence of predisposing
factors, autoimmune diseases are uncommon in the general pop-
ulation with a prevalence of 7.6–9.4% (Cooper et al., 2009). With
these caveats in mind, this review will build a framework to
better understand the role of cell death in the current pathogenic
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model of systemic autoimmune diseases with an emphasis on the
neutrophil and suggest four theories which integrate NETosis into
the existing paradigm.
THE EXISTING PATHOGENIC MODEL OF CELL DEATH AS A
SOURCE OF AUTOANTIGENS IN SYSTEMIC AUTOIMMUNE
DISEASES
A HISTORICAL PERSPECTIVE
The ﬁrst evidence that suggested a role for cell death in autoim-
mune disease pathogenesis came from studies by Schwentker and
Rivers (1934) in the early 1930s. In these studies, immuniza-
tion of rabbits with homologous brain suffering autolysis (i.e.,
spontaneous necrosis) induced anti-brain antibodies and in some
cases paralysis, while immunization with freshly isolated brain
did not. Although no direct association was made between cell
death and the development anti-brain autoantibodies, this obser-
vation supported the growing idea that allergic encephalomyelitis
and other antibody-mediated diseases may result from autoim-
munization against altered tissue generated by the action of
pathogens, toxins, chemicals, and/or physical agents (Zoutendyk
and Gear, 1951). Later, Burnet (1959) proposed that immune
cells reactive with antigenic determinants not readily accessible
to the immune system (only in inﬂamed or traumatized organs)
may not be eliminated and be responsible for inducing a vicious
cycle of inﬂammation, most readily when the organism is under
stress. This was an important step in recognizing that normally
sequestered or altered self-proteins may drive autoimmunity by
stimulating autoreactive cells that were not eliminated or rendered
tolerogenic during development.
The seminal description of apoptosis as a programmed form of
cell death, distinct from necrosis, in 1972, inﬂuenced subsequent
studies of cell death and ultimately shaped our current pathogenic
model of autoimmune diseases (Kerr et al., 1972). It is likely that
if another form of programmed cell death had been identiﬁed at
that time (e.g., necroptosis or NETosis), the current paradigm of
cell death and autoimmune disease pathogenesis, may very well
center around a different form of death. A central role for apopto-
sis in autoimmune disease pathogenesis began to emerge in 1990
when two studies provided evidence that apoptosis was a driver of
inﬂammation in autoimmunity. Bell and colleagues observed that
nucleosomes released from cells dying by apoptosis could stimu-
late the production of anti-DNA antibodies in vitro, and suggested
that this process may occur in vivo in SLE (Bell et al., 1990; Bell
andMorrison, 1991). Rumore and Steinman (1990) identiﬁed that
patients with SLE have circulating DNA “closely resembling the
characteristic 200 bp ladder found with oligonucleosomal DNA,”
and suggested that this DNA may be produced by apoptotic cells.
They also suggested the possibility that oligonucleosomal DNA
generated during apoptosis may escape phagocytosis, and thus
gain access to the extracellular ﬂuid. Later, soluble nucleosomal
DNA was found in circulation in other autoimmune diseases
including SS, scleroderma, and anti-neutrophil cytoplasm anti-
bodies (ANCA)-associated vasculitis (Holdenrieder et al., 2006),
as well as in synovial ﬂuid in RA (Yu et al., 1997).
Although the model linking apoptosis to the pathogenesis
of autoimmune diseases was gaining momentum, there was no
direct evidence that dead or dying cells were active participants
in the process. This culminated in 1994 when two papers were
published that placed the apoptotic cell in the spotlight as an
important factor in SLE pathogenesis. The ﬁrst paper, by Emlen
et al. (1994), described that patients with SLE have accelerated
lymphocyte apoptosis in vitro and suggested that“abnormal apop-
tosis of lymphocytes in SLE may provide a source of extracellular
nuclear antigen to drive the immune response and to allow the
formation of immune complexes (IC).” Shortly thereafter, a paper
by Casciola-Rosen et al. (1994) revealed that SLE autoantigens
clustered at the surface of apoptotic blebs (membrane protru-
sions that form on cells dying by apoptosis). The novelty of this
paper was that it showed a model in which not only DNA, but
other autoantigens (i.e., ribonucleoproteins, RNP) are potentially
exposed to the immune systemduring apoptosis. Moreover, it pro-
posed that during this process, autoantigens can suffer changes in
immunogenicity as result of clustering and potentially through
posttranslational modiﬁcations.
Based on these studies as well as several others, apoptosis has
become a critical part of the pathogenic model of autoimmune
diseases, and has been widely considered to be the source of
autoantigens (e.g., DNA and RNP) and adjuvants (e.g., HMGB-1)
that can initiate and propagate the autoimmune process (Lovgren
et al., 2004; Vollmer et al., 2005; Marshak-Rothstein and Rifkin,
2007; Urbonaviciute et al., 2008). However, since apoptotic cells
are largely considered anti-inﬂammatory, secondary necrosis of
apoptotic cells is a further step that is necessary in this model to
expose the cellular contents of dying cells to the immune system.
The extracellular exposure of intracellular antigens and endoge-
nous adjuvants, together with the abnormal clearance and/or
response to these molecules is the most widely-accepted hypoth-
esis in the paradigm of autoantibody production and systemic
autoimmunity (Suber et al., 2008; Munoz et al., 2010; Mahoney
et al., 2011; Wickman et al., 2012).
THE COMPLEXITY OF CELL DEATH
THREE MAIN CATEGORIES OF CELL DEATH
Given the wide acceptance of the hypothesis that apoptosis plays
a central role in autoimmune disease pathogenesis, it is surprising
that no successful therapeutics have been developed which target
this pathway in human autoimmune diseases (e.g., to improve the
clearance of dying cells). If we accept that cell death is playing an
important role, this likely reﬂects a lack of understanding of the
vast complexity of cell death mechanisms, something that is only
beginning to be appreciated. According to the last recommenda-
tions of the “Nomenclature Committee on Cell Death,” cell death
can be divided into three major groups: programmed, regulated,
and accidental (Galluzzi et al., 2012). “Programmed” applies to
those physiological instances of cell death that occur in the context
of embryonic/post-embryonic development and tissue homeosta-
sis (e.g., apoptosis and necroptosis). “Regulated”is used to indicate
cases of cell death – be they programmed or not – whose initiation
and/or execution is mediated by a dedicated molecular machinery,
implying that they can be inhibited by targeted pharmacological
and/or genetic interventions (e.g., autophagic death and NETosis).
“Accidental” indicates cell death triggered by extremely harsh phys-
ical conditions (e.g., freeze–thawing cycles or high concentrations
of pro-oxidants), which cannot be inhibited by pharmacological
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and/or genetic manipulation and usually exhibits morphological
features of necrosis.
A form of “accidental death” is secondary necrosis, which is
deﬁned as an autolytic process of cell disintegration with release of
cell components that occurs when there is no intervention of scav-
engers after cell death is completed (Silva, 2010). In this regard, it
is important to distinguish accidental necrosis from programmed
necrosis or necroptosis, a tightly controlled programmed form
of death with morphological resemblance of necrosis, but that
is orchestrated by the serine-threonine kinases RIP1 and RIP3,
and can be speciﬁcally inhibited by necrostatins (Wu et al., 2012).
Necroptosis may play a regulatory role in the development of the
immune system and in the response to viral infection by serving as
a backup mechanism of cell death if apoptosis is impaired (Kaiser
et al., 2011; Oberst et al., 2011; Zhang et al., 2011; Mocarski et al.,
2012). In principle, every form of programmed and regulated
cell death may be at risk of suffering secondary necrosis if efﬁ-
cient clearance is delayed. Therefore, although secondary necrosis
has been long considered a consequence of inappropriate clear-
ance of apoptotic cells (Silva, 2010), it is possible that secondary
necrosis may result from any form of death in which the corps is
inadequately cleared.
PROGRAMMED AND REGULATED CELL DEATH
To date, 13 modes of programmed and regulated cell death have
been proposed based on biochemical pathways, the effect of spe-
ciﬁc death inhibitors, and morphological changes occurring in the
dying cell and its organelles (reviewed in Galluzzi et al., 2012).
The induction of each form of death depends on different factors
including the cell type, the death stimuli, the cytokine envi-
ronment, the presence of pathogens, and the presence of death
inhibitors, among others. Thus, death by pyroptosis (a caspase-1-
dependent process activated by intracellular bacteria) is restricted
to macrophages and dendritic cells (DCs), ETosis (also referred
as NETosis when occurs in neutrophils) appears to be speciﬁc for
granulocytes, and corniﬁcation (a program of terminal differenti-
ation that is dependent on caspase-14) is limited to keratinocytes
(Galluzzi et al., 2012). Moreover, death signals can be modulated
to trigger different forms of death. For example, although sig-
nals from members of the tumor necrosis factor receptor (TNFR)
family activate the caspase cascade to induce death by apoptosis,
inhibition of caspase-8 (e.g., by virus infection) changes the death
pathway toward programmednecrosis (i.e., necroptosis; Han et al.,
2011; Mocarski et al., 2012). Interestingly, lupus T cells exhibit
persistent mitochondrial hyperpolarization as well as depletion
of ATP and glutathione, which results in the induction of necrosis
(likely necroptosis), instead of apoptosis, in response to activation-
induced death (Gergely et al., 2002; Fernandez and Perl, 2009;
Fernandez and Perl, 2010).
Cytokines add an additional level of complexity by modulat-
ing pathways that promote cell survival, cell death, and the mode
of death. For example, in the case of neutrophils which are pro-
grammed to undergo spontaneous apoptosis as a mechanism to
maintain immune system homeostasis, granulocyte-macrophage
colony-stimulating factor (GM-CSF) can delay this process and
prolong neutrophil survival (Geering and Simon, 2011). How-
ever, when neutrophils are exposed to GM-CSF upon ligation of
CD44, the cells die by an autophagy-related form of neutrophil
necroptosis (Mihalache et al., 2011). Moreover, if GM-CSF primed
neutrophils are exposed to LPS or complement factor 5a (C5a),
the cells generate a unique form of neutrophil extracellular traps
(NETs) made of mitochondrial DNA (Youseﬁ et al., 2009).
In cells that may contain more than one death program, there is
the potential to select speciﬁc modes of death depending on stim-
uli in the environment. However, once the cell is committed to
die by one speciﬁc form of death, this program appears to be irre-
versible and in some cases incompatible with other forms of death
(at least for in vitro studies). Thus, there are types of death that
seem to be antagonistic (i.e., they cannot co-exist in the same cell)
because the activation of one death pathway inhibits the others,
for example, apoptosis and NETosis or apoptosis and necropto-
sis (Galluzzi et al., 2012). The capacity to activate diverse forms
of death appears to provide an advantage to the host by switching
modes of death under conditions in which speciﬁc death pathways
may be inhibited, for example, in the clearance of pathogens by
necroptosiswhen apoptosis is inhibited (Han et al., 2011; Mocarski
et al., 2012). The development of highly speciﬁc probes and abil-
ity to study cell death in vivo will be critical to determine what
form of cell death predominates in a given target tissue and may
provide valuable insights into the pathogenesis of autoimmune
diseases. This is particularly relevant in the study of cells that con-
tain multiple death programs and are known to be present in areas
of inﬂammation, such as neutrophils.
PROGRAMMED AND REGULATED CELL DEATH IN
NEUTROPHIL FUNCTION AND HOMEOSTASIS
Among the different modes of programmed and regulated cell
death, at least four types have beendescribed inneutrophils. Apop-
tosis and NETosis, which are known to occur in vivo (Yipp et al.,
2012), and autophagic-like cell death and an autophagy-related
form of necroptosis, which have been induced in vitro (von and
Simon, 2007; Mihalache et al., 2011). Although autophagic cell
death and programmed necrosis have been implicated in control-
ling both innate and adaptive immune functions (Lu and Walsh,
2012), the role of these forms of death in neutrophil function
and their potential consequences in autoimmunity still need to be
deﬁned.
NEUTROPHIL APOPTOSIS AND NETOSIS: PARTNERS IN THE FIGHT
AGAINST PATHOGENS
Neutrophils are unique cells that use death as a mechanism to
modulate inﬂammation and to ensure the efﬁcient clearance of
microorganisms during infections. Two forms of neutrophil death
have been implicated in these processes, apoptosis and NETosis.
Apoptosis is the mechanism by which aged neutrophils con-
stitutively die in order to maintain homeostatic cell numbers
(Cartwright et al., 1964; Geering and Simon, 2011). In addi-
tion, apoptosis plays a critical role in the innate response against
bacterial, fungal, and protozoal infections (reviewed in Kennedy
and DeLeo, 2009; Geering and Simon, 2011). During infection,
neutrophils phagocytose bacteria, fungi and protozoa, and the
ingested microorganisms are destroyed by the combination of
reactive oxygen species (ROS) and antimicrobial granule compo-
nents. Neutrophils contain or produce many cytotoxic molecules
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that can cause signiﬁcant damage to surrounding tissues if the
inﬂammatory response is not tightly regulated. The engulfment
of microorganisms by neutrophils typically accelerates neutrophil
apoptosis, which ultimately promotes the resolution of infec-
tion. Thus, neutrophil apoptosis guaranties the safe disposal
of engulfed bacteria, leads to a loss of functional properties
in neutrophils, and drives the production of anti-inﬂammatory
cytokines through clearance of the apoptotic cells by resident or
inﬁltrating macrophages.
Neutrophils also die by NETosis in response to pathogens.
During this process, neutrophils extrude extracellular ﬁbrillary
networks composed of DNA associatedwith histones and granular
antimicrobial proteins such as proteinase 3 (PR3), myeloperoxi-
dase (MPO), and α-defensins, among others (Urban et al., 2009).
NETs act as a mesh that traps microorganisms and facilitates their
interaction with neutrophil-derived effector molecules, limiting
the spread of rapidly disseminating pathogens (Brinkmann et al.,
2004). In addition, NETs can induce the production of antimi-
crobial cytokines, such as interferon-α (IFN-α; Garcia-Romo
et al., 2011; Lande et al., 2011; Villanueva et al., 2011), a relevant
cytokine in the control of viral, bacterial, and protozoal infec-
tions (Bogdan et al., 2004). Thus, although neutrophil apoptosis
and NETosis have been studied as separate processes that occur
during infection, it is more likely that these death pathways co-
exist and work cooperatively for the safe and efﬁcient clearance
of pathogens by limiting pathogen spreading, activating inﬂam-
matory antimicrobial pathways, and promoting the resolution of
inﬂammation.
Interestingly, although neutrophils are theoretically exposed to
the same environmental stimuli during infection, it is intriguing
that some neutrophils become phagocytic and die by apoptosis,
while others become NETotic. Indeed, in mouse neutrophils in
which NETs were induced by IL-8 priming and exposure to S.
ﬂexneri, only a fraction (13.9 ± 1.8%) formed NETs (Li et al.,
2010). Thus, it is possible that this differential response may
result from distinct populations of neutrophils which are speciﬁ-
cally programmed to activate apoptosis or NETosis in response to
pathogens or cytokines. Alternatively, cytokines and/or growth
factors that alter the default death program of neutrophils to
prolong their survival during infection (e.g., GM-CSF) may
allow neutrophils not yet committed to die by apoptosis to
release NETs.
NETs vs NETosis
Since the description of NETs, it has been controversial whether
neutrophils die while extruding their intracellular material and
if this phenomenon occurs in vivo. Initial in vitro studies using
the non-physiological stimulus, phorbol-12-myristate-13-acetate
(PMA), demonstrated that formation of NETs required rupture
of the cell membrane in a process marked by increased cell per-
meability and exposure of inner membrane phospholipids (Fuchs
et al., 2007). Although this processwas clearly distinguishable from
apoptosis and necrosis, the striking damage suffered by the cell
supported the notion that the production of NETs was associated
with neutrophil death (i.e., NETosis). In this model, NET forma-
tion required cell death, resulting in the terms NETs and NETosis
being used interchangeably.
However, further studies demonstrated that when using more
physiological stimuli (i.e., GM-CSF priming and subsequent
short-term TLR4 ligation or C5a receptor stimulation), NETs are
generated by viable cells (Youseﬁ et al., 2009). A recent study by
Yipp et al. (2012) elegantly suggests a novel paradigm in NET
formation. By directly visualizing neutrophil behavior during
Gram-positive skin infections in mice and humans, it was demon-
strated that viable neutrophils formNETswhile crawling, resulting
in widespread NET deposition in tissue. As result of this process,
neutrophils were rendered anuclear, but did not lyse or exhibit
features of programmed cell death. In fact, anuclear neutrophils
contained bacteria, suggesting that phagolysosome maturation
and NET release can be separately compartmentalized, such that
bacteria cannot escape from inside the cell during NET forma-
tion. Whether the anuclear neutrophil should or should not be
considered dead is questionable, and it remains unclear if these
cells retain the capacity to activate other death programs. In this
regard, it is important to note that similar to erythrocytes and
platelets (Mason et al., 2007; Lang and Qadri, 2012), cytoplasts
(anuclear neutrophils generated in vitro) retain full capacity to
die by apoptosis (Maianski et al., 2004). In this scenario, death
by apoptosis of post-NET anuclear neutrophils may guaranty
the safe disposal of engulfed bacteria, their efﬁcient clearance to
avoid secondary necrosis, and the induction of anti-inﬂammatory
cytokines by phagocytes. For practical reasons we will continue
using the term NETosis as a form of death, although it may be
somewhat inaccurate. Although further study is needed to under-
stand the interplay between death programs in the neutrophil, it is
clear that distinct cell death mechanisms may be active in systemic
autoimmune diseases and contribute differentially to the initiation
and propagation of disease.
CLEARANCE OF DEAD CELLS AND AUTOIMMUNITY
MECHANISMS OF DEAD CELL CLEARANCE ARE NOT UNIQUE TO
APOPTOTIC CELLS
Programmed and regulated forms of cell death are physiologic
processes that play critical roles in many different aspects of host
development and homeostasis, including tissue turnover, proper
development, and the elimination of transformed and infected
cells. The rapid and efﬁcient clearance of dead cells and debris is
therefore critical to prevent the accumulation of aged, damaged,
infected, or dangerous cells. Although the study of apoptosis has
brought about an important understanding of pathways activated
bydying cells thatmodulate inﬂammation, immune tolerance, and
the efﬁcient clearance of cell debris (reviewed in Ravichandran,
2011;Wickman et al., 2012), similarmechanismsmust exist for any
form of programmed or regulated cell death in order to maintain
host homeostasis.
During apoptosis, dying cells advertise their presence to phago-
cytes through the release of soluble “ﬁnd-me” signals (e.g., the
lipid lysophosphatidylcholine, sphingosine 1-phosphate,CX3CL1,
and the nucleotides ATP and UTP), which induce migration of
phagocytes toward the dying cells. Apoptotic cells also expose
“eat-me”signals on their surface (e.g., phosphatidylserine, PS) that
are recognized by phagocytes through speciﬁc engulfment recep-
tors. Interestingly, other forms of death including anoikis (death
inducedbydetachmentof anchorage-dependent cells), autophagic
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cell death, caspase-independent apoptosis, and necroptosis also
expose PS as a mechanism for efﬁcient non-inﬂammatory clear-
ance by phagocytes (Hirt and Leist, 2003; Brouckaert et al., 2004;
Petrovski et al., 2007a, 2011). In addition, cells dying by anoikis
andnecroptosis are efﬁciently engulfed byPS-independent process
(Hirt et al., 2000; Petrovski et al., 2007a, 2011).
Efﬁcient mechanisms of clearance are not limited to the recog-
nition and engulfment of intact dead cells, but include pathways
that recognize and remove necrotic cell fragments and cell debris
such asDNA,histones, andRNP.Thesepathwayshave thepotential
to be universal in the clearance of cell debris generated indepen-
dently of themode of cell death. For example, necrotic lymphocyte
debris is efﬁciently removed by macrophages via PS, αvβ3, CD14,
CD36, and complement C1q (Bottcher et al., 2006), and debris
from neutrophils dying by secondary necrosis is cleared by path-
ways involving thrombospondin-1 and αvβ3 (Ren et al., 2001). In
both cases, cell debris is removed without eliciting inﬂammatory
cytokine secretion. Pentraxins such as C-reactive protein (CRP),
serum amyloid P component (SAP), and pentraxin 3 (PTX3) are
also involved in the clearance of damaged cells and their solu-
ble constituents. CRP binds to the membranes of damaged cells
(both apoptotic and necrotic) likely via phosphatidylcholine, con-
tributing to clearance by phagocytes (Volanakis and Wirtz, 1979;
Gershov et al., 2000; Hart et al., 2005; Krysko et al., 2006). In addi-
tion, CRP binds to small nuclear RNP particles and chromatin (via
histones) and is believe to be involved in the clearance of poten-
tially autoantigenic nuclear material released from dying cells (Du
Clos et al., 1988; Du Clos, 1989; Jewell et al., 1993). The avid bind-
ing of SAP to chromatin displaces H1-type histones, solubilizing
chromatin fragments otherwise quite insoluble at the physiologi-
cal ionic strength of extracellular ﬂuids (Butler et al., 1990). Since
SAP binds to chromatin exposed by necrotic and apoptotic cells
in vivo (Hintner et al., 1988; Breathnach et al., 1989), it may par-
ticipate in the disposal of chromatin exposed during cell death,
potentially including DNA found in NETs.
Components of the complement pathway are also important in
the clearance of dead cells. Early components of the component
complement classical pathway bind to cells undergoing secondary
necrosis, promoting their engulfment by phagocytes (Gullstrand
et al., 2009). In addition, C1q binds DNA and, together with
DNase I, promotes degradation of necrotic cell-derived chromatin
(Gaipl et al., 2004). The complement inhibitor C4b-binding pro-
tein (C4BP) binds strongly to necrotic cells, limiting DNA release
from these permeable cells and inhibits the complement cascade
at the level of C3 (Trouw et al., 2005).
Chromatin released from dying cells is normally degraded
by serum endonucleases, such as DNase I (Napirei et al., 2004;
Nathan, 2006). In this regard, although antimicrobial peptides
and C1q appear to protect NET DNA from DNase I degradation
(Lande et al., 2011; Lefﬂer et al., 2012; a process likely required to
enhance NET antimicrobial activity), serum from healthy controls
efﬁciently degrades NETs (Hakkim et al., 2010; Lefﬂer et al., 2012),
suggesting the existence of additional mechanisms of NET clear-
ance. Certainly, further studies are necessary to deﬁne the role of
known and novel clearance pathways in the removal of cells dying
by newly discovered forms of cell death and determine how these
processes modulate inﬂammation in infection and autoimmunity.
IMPAIRED CLEARANCE OF DEAD CELLS AND AUTOIMMUNITY:
INSIGHTS FROM IN VIVO SYSTEMS
The existence of clearance defects is critical to support the current
model of cell death in autoimmunity, yet there are still important
gaps in the knowledge of relevant pathways that can be modu-
lated by therapy and the forms of death responsible for driving
autoimmune diseases in humans. Complete genetic deﬁciencies
in components involved in the clearance of dead cells are very
uncommon in humans and limited to a few pathways (e.g., early
components of complement and DNases; Yasutomo et al., 2001;
Manderson et al., 2004; Al-Mayouf et al., 2011) but are strikingly
associated with SLE, suggesting that these pathways are relevant
in the protection against autoimmunity. However, while these
ﬁndings have been considered strong evidence to support the
role of apoptosis in autoimmunity, it is important to highlight
that these pathways are also involved in the clearance of dead
cells generated by other mechanisms (e.g., NETosis and necrop-
tosis). In this regard, clearance defects cannot be used as direct
evidence that apoptosis alone is responsible for triggering auto-
immunity.
The study of mice with targeted disruption of speciﬁc genes
associated with the clearance of dying cells (assuming that this
is the only function of these genes) have been used to support
the role of apoptosis in autoimmunity, but some of these mod-
els have important caveats. Interestingly, although some of these
models develop lupus-like features and abnormal accumulation of
apoptotic cells (e.g., C1q-, C4-, SAP-, c-Mer-, DNase I-, and MFG-
E8-deﬁcient mice; Botto et al., 1998; Bickerstaff et al., 1999; Chen
et al., 2000; Napirei et al., 2000; Cohen et al., 2002; Hanayama et al.,
2004), disease expression is frequently dependent on background
genes (e.g., C1q-, C4-, SAP-deﬁcient mice; Botto et al., 1998; Bick-
erstaff et al., 1999; Chen et al., 2000; Mitchell et al., 2002; Paul
et al., 2002; Gillmore et al., 2004). In some cases, an increase in the
number of apoptotic bodies, although related to the targeted gene,
is not associated with disease expression (Mitchell et al., 1999).
Moreover, not all clearance defects in mice lead to autoimmu-
nity (e.g., CD14- and MBL-deﬁcient mice) despite an abnormal in
vivo accumulation of apoptotic material (Devitt et al., 2004; Stuart
et al., 2005).
These discrepancies suggest that the development of autoim-
munity is not solely dependent on the accumulation of apoptotic
cells and highlight the inﬂuence of background genes on disease
expression. Strikingly, it was demonstrated that the autoim-
mune phenotype described in some gene-targeted knock-out
mice (i.e., SAP-deﬁcient mice) might be primarily due to com-
binations of background genes originated from the parental
129 and C57BL/6 mouse strains (Bygrave et al., 2004; Heidari
et al., 2006; Carlucci et al., 2007; widely used in the generation
of gene-targeted mice, including the C1q-, C4, SAP-, DNase
I-, and MFG-E8-deﬁcient mice), which may or may not inter-
act with the target gene. In this scenario, although a targeted
gene may predispose to the accumulation of apoptotic cells
(e.g., C1q-deﬁcient mice); this may not necessarily be impor-
tant or sufﬁcient for development of the autoimmune phenotype
(Mitchell et al., 2002). These nuances are important to con-
sider when translating ﬁndings from these models to human
autoimmunity and reveal important limitations in interpreting
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the mechanistic link between the genetic predisposition to accu-
mulate apoptotic cells and development of disease. Further studies
are necessary to exclude the possibility that other forms of death
may also play a role or that other functions of these pathways
not related to clearance of dead cells are not responsible for
the development of autoimmunity (Carroll, 2004; Carroll and
Isenman, 2012).
DO NO HARM: A UNIVERSAL REQUIREMENT FOR
PHYSIOLOGIC CELL DEATH
The end point of any physiologic form of death is to carry out a
required function and be appropriately cleared, without deleteri-
ous effects to the host. However, although this process requires an
anti-inﬂammatory ending, each form of death has distinct inter-
actions and consequences on the immune system with pro- or
anti-inﬂammatory effects depending on themode of death and the
circumstances associated with the induction of cell death (Petro-
vski et al., 2007b; Miao et al., 2010; Johansson et al., 2011; Rock
et al., 2011; Han et al., 2011; Fesus et al., 2011; Remijsen et al., 2011;
Schiller et al., 2012). Thus, for example, while apoptotic cell death
occurring in steady-state conditions (e.g., duringdevelopment and
cell turnover) must be tolerogenic (Voll et al., 1997), induction of
tolerance could have harmful consequences in circumstances in
which apoptotic cell death is increased, but a pro-inﬂammatory
response is required (e.g., during infections and cancer). In this
scenario, there are factors (e.g., cytokines, pathogens and tumor
antigens) which modulate the response to apoptotic cells, allow-
ing the induction of adaptive immune responses if immunogenic
antigens are present (Le et al., 2003; Lin et al., 2008; Alfaro et al.,
2011; Rock et al., 2011; Johansson et al., 2011). Collectively, these
responses help to protect the host and limit the injurious pro-
cess, but can themselves cause tissue damage and disease. The
precise balance betweenpro- and anti-inﬂammatory effector func-
tions driven by dying cells and the surrounding immune players
is therefore critical to determine the net effect of dying cells.
When this balance is shifted, the consequences may drive an
autoimmune process or allow the uncontrolled growth of trans-
formed cells.
ANTI-INFLAMMATORY PATHWAYS INDUCED BY DEAD CELLS ARE NOT
LIMITED TO APOPTOSIS
The study of apoptosis provided initial clues that dying cells are
important players in limiting inﬂammation. However, since no
physiologic form of death should harm the host under normal
circumstances, it is likely that in addition to apoptosis, other
modes of death may have the capacity to provide signals to
resolve inﬂammation and/or promote healing. After ingestion of
apoptotic cells, phagocytes produce “tolerate me” cytokines (e.g.,
transforming growth factor β, TGF-β and IL-10), and decrease
secretion of pro-inﬂammatory cytokines (e.g., TNFα, IL-1, and
IL-12), which actively creates an anti-inﬂammatory milieu at sites
of apoptotic cell death (Voll et al., 1997; Munoz et al., 2010). Inter-
estingly, the efﬁcient engulfment of necroptotic cells also inhibits
the production of pro-inﬂammatory cytokines in macrophages
(Hirt and Leist, 2003; Bottcher et al., 2006). Intriguingly, despite
the view that necrotic cells are pro-inﬂammatory, some reports
suggest that the efﬁcient phagocytosis of these cells can also
trigger anti-inﬂammatory and tissue repair pathways (Li et al.,
2001; Ren et al., 2001; Bottcher et al., 2006). Moreover, engulfment
of necrotic neutrophils by immature DCs down-regulates CD80,
CD86, and CD40, rendering them unable to induce allogeneic
T cell responses (Clayton et al., 2003).
Although NETosis may be viewed as a dangerous form of death
based on recent associations with SLE, Wegener’s granulomato-
sis, and Felty’s syndrome, several antimicrobial proteins that are
enriched in NETs (e.g., α-defensins and the cathelicidin LL37;
Brinkmann et al., 2004; Lai and Gallo, 2009; Urban et al., 2009),
also have anti-inﬂammatory activities which favor resolution of
infection and repair of damaged tissues (reviewed in Lai andGallo,
2009). In macrophages, α-defensins inhibit the secretion of TNFα
and nitric oxide, and protect mice from a murine model of peri-
tonitis (Miles et al., 2009). LL37 can inhibit LPS-induced cytokine
release frommonocytes andprotectsmice against endotoxin shock
(Nagaoka et al., 2001). In addition, cathelicidins inhibit TLR4-
mediated DC maturation and cytokine release (Di et al., 2007).
LL37 also appears to play a role in skin wound healing by promot-
ing keratinocyte migration that is required for re-epithelialization
of the wound (Heilborn et al., 2003; Carretero et al., 2008). Inter-
estingly, patients with SLE have antibodies against α-defensins
(also known as human neutrophil peptides or HNPs) and LL37
(Lande et al., 2011) suggesting that autoantibodies may affect
the function of these antimicrobial peptides in the context of
inﬂammation and autoimmunity. Thus, by attenuating exacer-
bated inﬂammatory responses and stimulating certain beneﬁcial
aspects of inﬂammation, antimicrobial peptides in NETs may
have an important role in regulating and balancing inﬂammatory
responses. Indeed, recent evidence has shown that lupus-prone
mice which are unable to generate NETs due to a deﬁciency in
Nox-2 (phagocyte NADPH oxidase) have markedly exacerbated
lupus (Campbell et al., 2012), supporting the importance of NETs
in immune homeostasis.
AUTOANTIBODIES: POTENT ADJUVANTS THAT CHANGE THE
INFLAMMATORY FATE OF DEAD CELLS
Different circumstances can change the inﬂammatory outcome of
dying cells, including pathogens, cytokines, cellular transforma-
tion, and cell damage by toxic agents, among others (Casares et al.,
2005; Petrovski et al., 2007b; Miao et al., 2010; Fesus et al., 2011;
Han et al., 2011; Johansson et al., 2011; Remijsen et al., 2011; Rock
et al., 2011; Garg et al., 2012; Schiller et al., 2012). In 2002, Leadbet-
ter et al. (2002) revealed an unexpected mechanism that explained
how immune cells might perceive autoantigens (generated under
sterile and/or non-toxic conditions) as noxious structures or
DAMPs (damage-associated molecular patterns), provoking the
production of pro-inﬂammatory cytokines. By studying mecha-
nisms that activated transgenic rheumatoid factor (RF)-B cells,
they demonstrated that IC consisting of IgG bound to mam-
malian chromatin effectively activated RF-B cell through a dual
process involving B cell antigen receptor (BCR) recognition and
delivery of the DNA to TLR9 sequestered in endosomal com-
partments. A few years later, the same group demonstrated that
the “two-receptor” paradigm can be extended to IC containing
RNA-associated autoantigens by dual BCR and TLR7 engagement
(Lau et al., 2005).
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Based on this model, further studies identiﬁed that although
apoptotic and necrotic material has minimal inﬂammatory activ-
ity, autoantibodies could convert cell debris into a potent inducer
of IFN-α by plasmocytoid dendritic cells (pDCs) via TLRs and
FcγRIIa ligation (Bave et al., 2000, 2001, 2003; Lovgren et al.,
2004). Similarly, although NETs can induce production of IFN-α
by pDCs (likely a physiologic response to aid in pathogen clear-
ance), this effect is strikingly enhanced (as much as 10-fold) by
the presence of IC containing NET components and antibodies
against DNA,HNP,or LL37,with anti-DNA antibodies as themost
prominent ampliﬁer of this response (Lande et al., 2011). A simi-
lar effect is likely responsible for the induction of IFN-α by pDCs
in the presence of NETs and anti-RNP antibodies (Garcia-Romo
et al., 2011).
The “two-receptor” paradigm has also been extended to spe-
ciﬁc autoantigens found in RA (Sokolove et al., 2011). Here, it
has been demonstrated that IC containing citrullinated ﬁbrino-
gen co-stimulate macrophages via the TLR4 and Fcγ receptor to
induce production of TNF-α by macrophages. Although ﬁbrino-
gen is not an intracellular antigen, it is possible that IC containing
citrullinated autoantigens released from dying cells may have a
similar inﬂammatory effect. Taken together, these data suggest
that under normal conditions, dying cells have the capacity to
modulate pro- and anti-inﬂammatory activities to avoidhost dam-
age. However, the presence of autoantibodies against components
released by dying cells shifts this balance toward an abnormal pro-
inﬂammatory response. Although parallel studies are necessary to
determine if autoantigens released by different forms of cell death
have distinct inﬂammatory properties, the available data suggests
that autoantigens released from any source have the same capacity
to form IC with autoantibodies and activate the immune system.
NEUTROPHILS IN SYSTEMIC AUTOIMMUNE DISEASES
Since the discovery of NETs, there has been renewed interest
in the neutrophil as a potential driver of autoimmune disease.
The neutrophil has long been implicated in playing a variety
of roles in systemic autoimmune diseases from immune effec-
tor to autoantigenic target. This stems from the ability of the
neutrophil to wear many different hats during the course of an
immune response from phagocyte, to secretor of cytokines, pro-
ducer of anti-bacterial agents andNETs, and stimulator of adaptive
immune cells. The primary role of the short-lived neutrophil in
host defense is to rapidly accumulate at sights of tissue injury, in
the presence or absence of infection, to protect against invasion by
bacteria or fungi and then die by the mechanisms described above
(Nathan, 2006).
While neutrophils are present in high numbers at the sites of
autoimmune damage and are thought to play active role in dis-
ease pathogenesis, theirmechanistic role in autoimmunity remains
unclear. Neutrophils and leukocytoclasia (i.e., neutrophil debris)
are the dominant inﬁltrate in vasculitis affecting small vessels in
systemic autoimmune diseases (Carlson and Chen, 2006), and
neutrophils are the second most abundant inﬁltrating cell type
in dermatomyositis (DM) skin lesions (Caproni et al., 2004). In
SLE, increased levels of apoptotic (Courtney et al., 1999), acti-
vated (Molad et al., 1994), and immature neutrophils (Bennett
et al., 2003) are found circulating in the blood of patients, and
the percentage of apoptotic and activated neutrophils positively
correlates with disease activity (Courtney et al., 1999). Further-
more, neutrophils are the most abundant cell type present in RA
synovial ﬂuid and are enriched at the pannus/cartilage interface,
where most tissue damage occurs (Mohr et al., 1981).
AUTOANTIGEN EXPRESSION BY NEUTROPHILS
Interestingly, the neutrophil is also thought to be a major source
of autoantigens in systemic autoimmune diseases. Neutrophil-
speciﬁc autoimmunity, which is strikingly associated with the
small-vessel vasculitides (i.e., microscopic polyangiitis, Wegener’s
granulomatosis, Churg–Strauss syndrome, and polyarteritis
nodosa), was ﬁrst reported in 1982 with the identiﬁcation of
ANCAs in a few patients with necrotizing glomerulonephritis
(Davies et al., 1982). MPO and PR3 were subsequently identiﬁed
as the predominant autoantigens in 1988 and 1990, respectively
(Falk and Jennette, 1988; Ludemann et al., 1990). Anti-neutrophil
autoantibodies (not necessarily targeting MPO and PR3) have also
been described in SS and SLE (Lamour et al., 1995; Manolova et al.,
2001), with recent evidence that neutrophil antimicrobial pep-
tides are among the antigens targeted in SLE (Lande et al., 2011).
It is also important to note that neutrophils express high levels
of peptidylarginine deiminase enzymes (PAD2 and PAD4; Darrah
et al., 2012), which are responsible for generating citrullinated pro-
teins, currently the most speciﬁc targets of the immune response
deﬁned in RA (Wegner et al., 2010). Thus, it appears that patients
with different forms of systemic autoimmunity target ubiquitously
expressed proteins as well as those uniquely expressed by neu-
trophils. The reason that several neutrophil-speciﬁc proteins are
targeted remains unclear, but may be related to their propensity
to die at sites of inﬂammation resulting in exposure of normally
sequestered antigens to the immune system.
MODIFIED DURING DEATH: A UNIFYING PROPERTY OF
AUTOANTIGENS
Clustering and structural modiﬁcation of autoantigens during
apoptosis meets two key requirements for breaking tolerance to
self-proteins: accessibility of the antigen to the immune system
(i.e., through clustering in apoptotic blebs) and non-homeostatic
state of the protein/altered self (i.e., through non-tolerized post-
translational modiﬁcations, PTMs). These features initially made
apoptosis an attractive central component of the autoimmune
disease paradigm (Casciola-Rosen et al., 1994; Hall et al., 2004).
However, although these requirements might be highly relevant
to autoimmune disease pathogenesis, they have the capacity to be
met by other forms of cell death.
Unbiased proteomic analysis of NETs by two different groups
have identiﬁed a total of 23 proteins present in these structures
(Urban et al., 2009; Saffarzadeh et al., 2012), and two additional
components have been described in other studies, including
LL37 (Lande et al., 2011) and DNA/chromatin (Brinkmann et al.,
2004; Table 1). These components have diverse functions and
subcellular distributions in live cells, but are redistributed and
extruded from neutrophils during NETosis. A literature search
revealed that 84% of NET components have been identiﬁed as
autoantigens in patients with autoimmunity, cancer, or both, in
independent studies (Table 1; Figure 1A). In fact, 74% have
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Table 1 | Autoantigens are enriched in NETs.
NET-protein Autoantigen Disease family Disease Reference
Actin, cytoplamsmic 1 and 2 (β/γ)*,ψ Yes Autoimmunity RA Darrah et al. (2012)
α-Actinin 1 and/or 4* Yes Autoimmunity SLE nephritis Renaudineau et al. (2007)




Iaccarino et al. (2011)
Brichory et al. (2001)
Azurocidin* Yes Autoimmunity Vasculitis Zhao et al. (1995)
Catalase* Yes Autoimmunity SLE
RA
Mansour et al. (2008)
Cathepsin G* yes Autoimmunity Vasculitis Schultz andTozman (1995)
Cytokeratin-10* Yes Infection-induced
autoimmunity
Chronic Lyme arthritis Ghosh et al. (2006)
Neutrophil defensins (HNP)*,£ yes Autoimmunity SLE Lande et al. (2011)
dsDNA/chromatin$ Yes Autoimmunity SLE Shen et al. (1998)
Leukocyte elastase* Yes Autoimmunity Vasculitis Schultz andTozman (1995)
Leukocyte elastase inhibitorψ No
α-Enolase*,ψ Yes Autoimmunity RA Wegner et al. (2010)
Glyceraldehyde 3-phosphate
dehydrogenaseψ




Kolln et al. (2006)
Edassery et al. (2010)
Takasaki et al. (2004)
Buse et al. (2008)




Shen et al. (1998)
Shen et al. (1998)
Dwivedi et al. (2012)
Sokolove et al. (2012)
Lactoferrin*,ψ Yes Autoimmunity Autoimmune pancreatitis
RA
Vasculitis
Hayakawa et al. (2009)
Mulder et al. (1993)
Schultz andTozman (1995)
LL37£ Yes Autoimmunity SLE Lande et al. (2011)
Lysozyme C* Yes Autoimmunity Vasculitis Schultz andTozman (1995)
Myeloid cell nuclear differentiation
antigen*
No – – –
Myeloperoxidase*,ψ Yes Autoimmunity Vasculitis Schultz andTozman (1995)
Myosin-9* Yes Genetic autoimmunity APS-1 Lindh et al. (2012)
Plastin-2*,ψ Yes Cancer Non-Hodgkin’s lymphoma Ueda et al. (2008)
Proﬁlin-1ψ No – – –
Protein S100*,ψ No – – –
Proteinase 3* Yes Autoimmunity Vasculitis Schultz andTozman (1995)
Transketolase* Yes Autoimmunity Multiple sclerosis Lovato et al. (2008)
*Saffarzadeh et al. (2012); ψUrban et al. (2009); $ Brinkmann et al. (2004); £Lande et al. (2011).
APS-1, autoimmune polyendocrine syndrome type I.
been reported to be autoantigens in systemic autoimmune dis-
eases, most dominantly in SLE, RA, and vasculitis (Figures 1A,B).
This observation suggests that redistribution into NETs may be a
previously unappreciated unifying property of several autoanti-
gens targeted across the spectrum of autoimmune diseases and
cancer.
Interestingly, although the exposure of autoantigens is a
common feature shared by NETosis and apoptosis, which may
similarly balance their potential relevance in autoimmunity, it
is noteworthy that these processes are clearly distinguishable
by the exposed autoantigens and the way that these molecules
are structurally modiﬁed. Thus, in contrast to apoptotic blebs,
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FIGURE 1 | NET autoantigens. (A) Of the 25 NET components
identiﬁed, 84% have been reported as autoantigens in cancer,
autoimmunity, or other disorders. 74% of these proteins have been
reported to be the target of autoantibodies in systemic autoimmune
diseases. (B)The number of NET proteins reported to be
autoantigens in various diseases is quantiﬁed and reveals that
NET autoimmunity is most common in patients with vasculitis,
SLE, and RA.
major autoantigens in systemic autoimmune disease such as
RNPs (e.g., Ro, La, Sm, and U1-70K) are not found in NETs
(Urban et al., 2009; Villanueva et al., 2011; Saffarzadeh et al.,
2012). Similarly, it is unknown whether neutrophils dying by
NETosis expose phospholipids targeted by anti-phospholipid
antibodies.
Apoptotic and NETotic cells also generate different PTMs.
Depending on the stimuli, apoptotic cells can contain autoanti-
gens modiﬁed by proteolysis (induced by caspases and/or
granzymes), phosphorylation/dephosphorylation, photo-induced
damage, methylation, ADP-ribosilation, and transglutamination
(Casciola-Rosen et al., 1999; Rutjes et al., 1999; Hall et al., 2004;
Andrade et al., 2005; Dieker et al., 2007; Utz et al., 1997, 2000;
Darrah and Rosen, 2010; van Bavel et al., 2011; Bernard et al.,
2012). In some cases, these modiﬁcations can be recognized by
autoantibodies (e.g., phosphorylation, acetylation, and methyla-
tion) and have been suggested to play a role in the loss of tolerance
to self-proteins. During NETosis, however, the induction of PTMs
appears to be more limited. In this regard, methylation, citrulli-
nation, and acetylation have been detected in histones (Liu et al.,
2012), but is unknown whether other autoantigens may be mod-
iﬁed during NETosis. Moreover, although histone citrullination
is a hallmark in NETs formation and a target for autoantibodies
in Felty’s syndrome (Li et al., 2010; Dwivedi et al., 2012), citrul-
lination of major autoantigens targeted in RA (e.g., enolase and
vimentin; Wegner et al., 2010) have not reported to occur during
NETosis. Although citrullination appears not to occur in apop-
totic cells dying by camptothecin or staurosporine (Neeli et al.,
2008), whether other apoptotic stimuli can activate citrullination
is unknown.
Apoptosis and NETosis may therefore have distinct features
(neither of which are mutually exclusive) that may offer different
advantages in the disease-speciﬁc paradigms of autoimmunity.
Thus, while the induction of protein citrullination, the exposure
of PR3 and MPO, and the extrusion of chromatin during NETosis
are attractive elements (but not exclusive for NETosis) for dis-
eases like RA, ANCA-associated vasculitis, and SLE, respectively,
features like the targeting of Ro and La and their association with
photosensitivity in SLE canbemore easily explainedbyultraviolet-
B (UVB)-induced keratinocyte apoptosis (Casciola-Rosen et al.,
1994) than by NETosis. Finally, it is unlikely that apoptosis and
NETosis are the only modes of death with the capacity to modify
protein immunogenicity, which may add layers of complexity to
the autoimmune paradigm and may support the development of
disease-speciﬁc models.
THEORICAL MODELS TO INTEGRATE NETOSIS AND
APOPTOSIS INTO THE PARADIGM OF SYSTEMIC
AUTOIMMUNE DISEASES
The ﬁnding that apoptotic cells and nucleosomal DNA are abnor-
mally increased in the circulation and target tissues of patientswith
systemic autoimmune diseases strongly supports the notion that
abnormal production and/or clearance of apoptotic cells is ongo-
ing in this group of diseases (Yu et al., 1997; Courtney et al., 1999;
Andrade et al., 2000; Makino et al., 2003; van Rossum et al., 2005;
Holdenrieder et al., 2006; Lin et al., 2007; Midgley et al., 2009). In
addition, apoptotic material in complex with autoantibodies can
induce production of IFN-α by pDCs (Bave et al., 2000, 2001, 2003;
Lovgren et al., 2004; Vollmer et al., 2005), a critical cytokine in the
current paradigm of SLE (Ronnblom et al., 2011) that is gaining
interest in the pathogenicmodel of SS, autoimmunemyositis, scle-
roderma, and RA (Greenberg et al., 2005; Hjelmervik et al., 2005;
Gottenberg et al., 2006; Walsh et al., 2007; Higgs et al., 2011, 2012;
van et al., 2011). However,while it iswidely accepted that apoptosis
is occurring in the setting of systemic autoimmunity, it remains
unclear if this process is an initiator of disease, a propagator of
the feed-forward cycle of immune-mediated tissue damage, or a
byproduct of unchecked inﬂammation.
These unanswered questions, together with the growth in our
understanding of the complexities of cell death, have sparked
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interest in other cell death programs that may be equally or more
important than apoptosis in driving autoimmunity. Recent studies
on NETotic cell death have demonstrated that similar to apoptotic
material, NETs (especially in complex with anti-NET antibodies)
can activate IFN-α production by pDCs (Garcia-Romo et al., 2011;
Lande et al., 2011; Villanueva et al., 2011), adding a novel mecha-
nistic player into SLE pathogenesis and potentially other systemic
autoimmune disease in which IFN-α may play a pathogenic role
(Knight and Kaplan, 2012). Moreover, NETs have been implicated
in the generation and release of autoantigens targeted in small-
vessel vasculitis and Felty’s syndrome (Kessenbrock et al., 2009;
Dwivedi et al., 2012). However, how NETosis may inﬂuence the
role of apoptosis in the model of systemic autoimmune diseases is
still unclear.
Based on the general concepts discussed in the initial part of
this review and recent experimental data, we will provide four
hypothetical models in an attempt to integrate apoptosis and
NETosis into a pathogenic paradigm of systemic autoimmunity.
It is not our intention to suggest that dying neutrophils are the
only source of autoantigens or the primary target during disease
initiation. Depending on the target tissue, many other cells can be
the primary source of autoantigens (e.g., keratinocytes, synovio-
cytes, lymphocytes, monocytes, platelets, myocytes, etc.) in which
case, the neutrophil may still play a role, but not as the origin of
autoantigens toward which tolerance is initially broken. In addi-
tion, considering that the growing literature in regard to NETs
and autoimmune diseases is biased toward SLE, these models will
be largely based upon this prototypic systemic autoimmune dis-
ease. Model I will discuss the possibility that defects in common
clearance pathways are the driver of systemic autoimmunity, while
models II–IV suggest that apoptosis andNETosis play independent
roles in systemic autoimmune disease pathogenesis. These three
additional models are largely based on three independent stud-
ies in 2011, which suggested that NETosis may play a pathogenic
role in SLE. While they agreed that NETs can induce IFN-α pro-
duction by pDCs (with some differences about the mechanism),
they differed dramatically in their conclusions about the mode by
which NETs are generated (Garcia-Romo et al., 2011; Lande et al.,
2011; Villanueva et al., 2011). These differences have major effects
on the development of a uniﬁed pathogenic model of systemic
autoimmunity.
THEORY I: THE SHARED MECHANISM MODEL
If systemic autoimmune diseases are the result of genetic or
acquired defects in universal clearance pathways, it is possible
that any form of cell death may provide the signals required to
activate an autoimmune response (Figure 2A). In this regard,
it is interesting that the same clearance defects that have been
used to support the role of apoptosis in autoimmune diseases
are now being translated into the NETotic model of autoimmu-
nity (e.g., impairment of DNase1 function; Martinez et al., 2008;
Hakkim et al., 2010). This suggests that diseases in which abnor-
mal accumulation or clearance of apoptotic and NETotic cells has
been implicated, may result from a common defect (e.g., SLE).
In this scenario, although some forms of death may dominate
at distinct disease stages depending on the environment (e.g.,
apoptosis, necroptosis, and/or autophagic cell death during viral
infections, but NETosis in bacterial or fungal infections); any form
of death may have the same potential to initiate and/or to prop-
agate the disease. Certainly, it is possible that unique autoantigen
modiﬁcations (e.g., cleavage by death proteases, phosphorylation,
and citrullination, among others; Hall et al., 2004; Darrah and
Rosen, 2010), generated by speciﬁc forms of death, may inﬂuence
autoantigen selection and disease phenotype. It is important to
determine if common clearance defects are playing a dominant
role in these diseases before attributing disease development to a
particular death pathway since therapies targeting unique forms
of death (e.g., NETosis or apoptosis) would have little effect in
this setting. Instead, therapies should be focused on enhancing
universal pathways involved in the anti-inﬂammatory clearance of
dead cells.
Attempts to improve the clearance of cell debris as therapy in
SLE have not been deeply explored. In 1959–1960, bovine DNase
I was ﬁrst used in a small number of patients with encouraging
results (Lachmann, 2003). However, following clinical improve-
ment, patients developed antibodies to the bovine DNase which
precluded further treatment. Forty years later, human recombi-
nant DNase I was used in patients with SLE in a Phase 1b trial
(Davis et al., 1999). Although this study did not identify clinical
beneﬁt, it was limited by the small number of patients and by
failure to achieve sufﬁcient bioactive serum concentrations. No
further studies have followed in the use of DNase or any other
component involved in the clearance of dead cells for the treatment
of SLE.
THEORY II: THE “APOPTOCENTRIC” MODEL
The study by Garcia-Romo et al. (2011), demonstrated that SLE
neutrophils undergo accelerated death in vitro (deﬁned by trypan
blue staining which indicates secondary necrosis) and identiﬁed
that these cells are dying by apoptosis (determined by TUNEL
assay). This data is consistent with previous observations both
in pediatric and adult SLE (Courtney et al., 1999; Midgley et al.,
2009), and supports the notion that in SLE, neutrophils are
actively dying by apoptosis and undergoing secondary necro-
sis. Interestingly, the presence of anti-RNP immunoglobulin (Ig)
induced a prominent reduction in the apoptosis rate of SLE neu-
trophils (in vitro) by changing the cell death program to NETosis.
Moreover, although they detected a prominent type-I IFN sig-
nature in SLE neutrophils, they found that neutrophils exposed
to IFN-α in vitro did not die by apoptosis and concluded that
IFN is not responsible for the accelerated apoptosis observed
in this cell type. Instead, they found that IFN-α increased the
expression of TLR7 in neutrophils, which made them more sus-
ceptible to die by RNP-Ig-induced NETosis via FcγRIIa/TLR7
ligation.
Although there are some aspects here that need further mech-
anistic analysis (like the switch from apoptosis to NETosis), this
data suggests a model in which apoptosis and NETosis co-exist
in the lupus paradigm, but have different roles in the disease
process (Figure 2B). Here, IFN-α activated neutrophils appear
to be a bystander target for autoantibodies, and NETosis is a
consequence of this process. In this model, the requirement of
TLR-ligation suggests that cells suffering from secondary necro-
sis (likely from the large pool of apoptotic neutrophils in SLE)
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FIGURE 2 |Theoretical models to integrate NETosis and apoptosis into
the paradigm of systemic autoimmune diseases.The four models are
depicted and illustrate the form of cell death that is predicted to play a role
during disease initiation and propagation. For simplicity, the neutrophil is
shown in all models as the initiating source of autoantigens, but other tissue
sources of cell death may be the primary driver of autoimmunity in models
(A,B). The neutrophil and large density granulocyte (LDG) are the primary
initiating sources of autoantigens in models (C) and (D), respectively. All
models require the impaired clearance of cell debris, activation of dendritic
cells and production of IFNα, and presentation of autoantigens to T helper
cells. T helper cells would then stimulate autoantibody production which may
lead to pro-inﬂammatory clearance of apoptotic cells and may combine with
IFNα to induce NET formation. The nuances of each model are depicted and
suggested therapeutic targets.
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play a role in disease initiation by releasing antigens (i.e., RNP)
to form IC which induce NETs. Together, this data suggest that in
accordancewith the apoptosis theory in SLE, accelerated apoptosis
(and/or clearance defects) are likely involved in disease initiation,
autoantibody production, and the early burst of IFN-α. Impor-
tantly, this model is not limited to apoptotic neutrophils, but
can be applied to apoptotic material generated from any tissue in
SLE. Induction of NETs by the effect of IFN-α and “two-receptor”
ligation of RNP-IC may be part of an amplifying process of dis-
ease propagation that enhances the exposure of autoantigens (i.e.,
DNA) and endogenous adjuvants (e.g., LL37) and stimulates fur-
ther IFN-α production in SLE. In this study, NETs induced by
RNP-IC can activate IFN-α production by pDCs independently of
FcγRIIa.
The recent ﬁnding that NETs are not necessary, but apparently
protective in lupus-prone mice further support the model that
NETs may be an epiphenomenon (at least in the lupus model),
and open the possibility that NETs may have important effects in
immunoregulation (Campbell et al., 2012). Although this ﬁnding
cannot be directly translated into the human model, it certainly
challenges investigators to better understand the role of NETs in
inﬂammation in humans, before considering it as a potential target
for therapy. Instead, therapies that correct the primary defect in
the apoptotic pathway or enhance apoptotic cell clearance may
have therapeutic beneﬁt.
THEORY III: THE “NETOCENTRIC” MODEL
The study by Lande et al. (2011) has novel features of inter-
est which support a primary role for NETosis in the initiation
and propagation of systemic autoimmunity (Figure 2C). First,
they discover that patients with SLE have circulating IC con-
taining DNA and neutrophil antimicrobial peptides (LL37 and
HNPs), and that a large proportion of patients have autoan-
tibodies against LL37 and HNP. Second, LL37 and HNP are
expressed on the surface of SLE neutrophils and this process is
likely induced by IFN-α. Third, mouse monoclonals against LL37
and HNP induced NETs in SLE neutrophils and in IFN-α primed
neutrophils. Finally, the study showed that freshly isolated SLE
neutrophils release DNA in culture and suggested that this pro-
cess reﬂects the spontaneous production of NETs by SLE patient
neutrophils. Although this study neither addressed whether circu-
lating IC containing DNA-LL37/HNPs are indeed generated from
NETs (but not other mode of neutrophil death), whether human
anti-LL37 and anti-HNP antibodies can trigger NET formation,
nor conﬁrmed that the DNA released spontaneously by SLE neu-
trophils was from NETs, the data suggests a model in which NET
production in SLE results from a vicious cycle whereby autoanti-
bodies targetNET components and induce furtherNET formation
by IFN-α activated neutrophils. In this study, although NETs
can induce IFN-α production by pDCs, this process is strongly
increased by IC formationwith anti-DNA,anti-LL37, or anti-HNP
antibodies.
This data supports a more “NETocentric” model that the pre-
vious one (Theory II) because the critical autoantigens that may
be sufﬁcient to initiate disease (i.e., DNA, LL37, and HNP) can
be directly exposed in NETs. Thus, in the context of an adequate
genetic predisposition, the abnormal clearance of NETs generated
during infection may predispose individuals to the production
of anti-DNA, anti-LL37, and anti-HNP antibodies. The presence
of these autoantibodies in combination with subsequent infec-
tions may amplify an interferogenic response until compensatory
mechanisms are surpassed, leading to disease propagation and
development of clinical symptoms. In this model, apoptosis may
occur as result of chronic inﬂammation and tissue damage induced
by NETs (likely providing additional autoantigens not expressed
in neutrophils), and suggests that the ﬁnding of accelerated apop-
tosis in SLE may correspond to an epiphenomenon not necessarily
associated with the induction of disease. In contrast to the previ-
ous models, therapies to improve NET clearance or decrease NET
production may be useful to ameliorate disease.
THEORY IV: THE LOW-DENSITY GRANULOCYTE-CENTRIC MODEL
The last model of NETs in systemic autoimmunity is based on the
study by Villanueva et al. (2011); Figure 2D. The major ﬁnding
in this study is strikingly different from the others (Garcia-Romo
et al., 2011; Lande et al., 2011); the authors conclude that that
low-density granulocytes (LDGs), but not mature neutrophils, are
responsible for generating NETs in SLE. LDGs appear to repre-
sent an immature form of granulocyte that is prematurely released
from the bone marrow in patients with SLE and RA (Hacbarth and
Kajdacsy-Balla, 1986; Denny et al., 2010). Because their morpho-
logical features are quite different from mature neutrophils, LDGs
are co-puriﬁed with mononuclear cells during peripheral blood
cell gradient separation using Ficoll-Hypaque. Contamination
with LDGs appears to be responsible for the prominent granu-
locytic signature found in peripheral mononuclear cells (PBMCs)
from patients with SLE (Bennett et al., 2003; Denny et al., 2010).
Strikingly,Villanueva et al. (2011) found that LDGs spontaneously
generate NETs immediately after puriﬁcation. However, in con-
trast to the data by Lande et al. (2011), mature SLE neutrophils
showed no differences in spontaneous NET formation compared
to controls.
There are some noteworthy features about LDGs that make
them unique as the source of NETs in SLE. Immature neutrophils
donot respond to type I IFN(e.g., IFN-α) because they fail to phos-
phorylate STAT1 (signal transducer and activator of transcrip-
tion 1) in response to receptor binding (Martinelli et al., 2004), a
feature likely shared by LDGs. This ﬁnding is consistent with gene
expression analysis of lupus LDGs in which among 302 differ-
entially expressed genes (compared to control neutrophils) there
is no evidence of IFN-induced gene activation (Villanueva et al.,
2011). Thus, thismay indirectly support the hypothesis that IFN-α
plays no role in the activation or generation of LDGs. Moreover,
in contrast to other studies in which the pre-existence of IFN-α
is required to prime neutrophils to generate NETs (Garcia-Romo
et al., 2011; Lande et al., 2011), this study suggests that IFN-αmay
have no role in inducing NETs by LDGs, providing a model in
which LDGs may precede IFN-α production in SLE. Instead, this
study shows that IL-17 is exposed in LDG-NETs, suggesting that
this cytokine may be involved in tissue damage and immune dys-
regulation induced by LDG-NETs. An intriguing part of this study
is that although SLE neutrophils do not generate NETs sponta-
neously; these cells in culture can release DNA (the mechanism
is undeﬁned) that can induce IFN-α mRNA expression by a pDC
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cell line in a similar proportion to LDG-NETs. In this study, the
effect of anti-NET antibodies on IFN-α production by pDCs was
not addressed.
It is still unknown whether circulating LDGs are found before
clinical disease initiation in SLE and the mechanism(s) by which
these cells are activated and abnormally released from bone mar-
row. However, it is possible that the abnormal release and NETosis
of LDGs (a process potentially boosted during infection) may be
the initial trigger for the aberrant production of IFN-α in SLE.
Moreover, abnormally cleared NETotic LDGs may serve as source
of autoantigens for autoantibodyproduction in SLE. In thismodel,
the abnormal apoptotic cell death found in SLE would be a conse-
quence of the autoimmune process and may contribute to disease
propagation, but is not the primary cause of disease. Importantly,
this model offers a unique and speciﬁc target (LDGs) of therapy
for the treatment of SLE.
CONCLUSION
The discovery of NETs has brought renewed interest in the neu-
trophil as a dominant player in the pathogenesis of systemic
autoimmune diseases. It is clear that NET formation by neu-
trophils is a biological phenomenonwith pathogenic potential, but
how this relates to apoptosis in the pathogenic model of systemic
autoimmune diseases remains undeﬁned. This review puts forth
several models to integrate the growing body of data on NETosis
with the historically appreciated role of apoptosis in these dis-
eases. The study of NETs is still in its infancy and in order to adopt
a new pathogenic model, further studies are necessary to deter-
mine how these structures and neutrophil remains (i.e., post-NET
anuclear neutrophils) modulate the immune response. Moreover,
the pathogenic mechanisms and pathways by which NETs are
generated need to be identiﬁed and will require the development
of highly speciﬁc probes to study these structures in vivo. Although
NETs can be distinguishedmorphologically when induced in vitro,
the study of NETs in tissues requires speciﬁc markers to clearly dis-
tinguishNETosis fromother types of granulocyte damage thatmay
release DNA and cytoplasmic contents (e.g., secondary necrosis).
In this regard, measuring soluble dsDNA (e.g., in plasma or in
supernatants; Margraf et al., 2008; Lande et al., 2011) to quantify
NETosis is questionable, since other forms of death (e.g., apopto-
sis and necrosis) may also be responsible for this effect (van der
Vaart and Pretorius, 2008), especially in diseases with a high rate
of apoptosis and secondary necrosis, such as SLE (Garcia-Romo
et al., 2011).
Undoubtedly, the early ﬁndings about the potential pro-
inﬂammatory effect of NETs are stimulating and have rejuvenated
the study of cell death in systemic autoimmune diseases. As more
forms of cell death are discovered and the growing complexity of
cell death is understood, it is important to reexamine the role of
different forms of cell death in the generation and modiﬁcation of
autoantigens. This will require the discovery of useful markers to
distinguish unique forms of death in blood and tissues and may
have important implications in the development of novel thera-
pies that target cell death pathways in the treatment of systemic
autoimmune diseases.
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